Although the risk is very small, we want women who are aware of reports of ALCL (anaplastic large cell lymphoma) in patients with silicone breast implants and saline. In the reported cases, ALCL are reported years after the surgery to place implants. In most of these cases, the women were diagnosed after observing changes in appearance or touch, in the area around the implant.
What advice would you give the FDA to women?
If a woman with breast implants do not have symptoms, the FDA does not recommend to do something about it. Women should continue to monitor their implants and performing periodic evaluations of the breast. The FDA does not recommend the implants removed.
Women who observe changes in the area around the implants, either sight or touch, including swelling or pain-must see your doctor for an evaluation.
Women who are considering breast implants should be aware that there is a small but growing risk of ALCL and discuss with your doctor.
How long before the FDA has more information on the subject?
Depending on the number of reports that you have, we have information to share soon. If you only received a few reports, it could take some time to get the information you’re looking for, such as in the case of a new type of ALCD and if the type of implant has an impact on the development of ALCL.
Find out more about breast implants and ALCL, visit the Center for Devices and Radiological Health at the FDA. If you have breast implants and has been diagnosed with ALCL, report it through the online program of the FDA, MedWatch (all reports are confidentiality as).
Possibly Related Articles:
